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Introduction: The knowledge and behaviour of adult patients with cystic fibrosis (CF) regarding cross-infection are ill understood.
Methods: A questionnaire was designed to investigate this at the West Midlands Adult CF Centre.
Results: 94 patients completed the questionnaire. 54%, 36% and 46% had “no idea” of the lifetime risk of contracting Burkholderia cepacia
complex, epidemic strains of Pseudomonas aeruginosa, and MRSA, respectively. 25–33% did not know the consequences of infection with
these bacteria. 35% mixed with other people with CF, 6.5% during physiotherapy or nebulizer use. Most respondents did not think quality of
life was significantly linked with segregation from other patients with CF.
Conclusions: Adults with CF, at least in the West Midlands, have poor knowledge of the risk and consequences of cross-infection. A
significant proportion ignored advice not to mix with other patients, although segregation was not thought to impact upon quality of life. This
suggests that more education about the risks of cross-infection would be beneficial.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cross-infection; Cystic fibrosis; Knowledge; Questionnaire1. Introduction
The majority of morbidity and mortality in cystic fibrosis is
due to disease of the respiratory system [1], which is
characterized by progressive bronchiectasis and airflow
obstruction. One of the main contributing factors to the
progressive lung damage is chronic bacterial infection. During
childhood Staphylococcus aureus and Haemophilus influen-
zae are the main respiratory pathogens [2,3]. In contrast, 80%
of patients reaching adulthood are colonized with Pseudomo-
nas aeruginosa, which is associated with increased lung
function decline and a higher mortality rate [3,4].
More recently, some centres have identified epidemic
colonization with Burkholderia cepacia complex or certain
strains of P. aeruginosa [3,5–10]. There is evidence that
these bacteria are both more pathogenic [11–14] and more⁎ Corresponding author. Tel.: +44 121 424 3731; fax: +44 121 424 1661.
E-mail address: djwaine@doctors.org.uk (D.J. Waine).
1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.10.006transmissible [15,16] than other strains, so most centres now
keep patients separate in clinic and advise patients not to mix
with other patients who have CF.
The majority of patients and carers in a paediatric setting
welcomed these infection control measures as a necessary
measure to reduce the risk of cross-infection and consequent
altered health status, but some reported a negative emotional
impact of not socializing with other patients and feelings of
alienation created by segregation [11]. There has been
considerable concern in the medical fraternity about the
potential negative impact of segregation on patients [17],
however the knowledge and attitudes of adult patients have
not been assessed. Furthermore, it has been demonstrated in
other areas that CF professionals are not necessarily able to
predict accurately the knowledge of their patients [18,19]
and that patients may have issues they would like to discuss,
but would prefer health professionals to raise them [20, 21].
We designed a descriptive questionnaire to investigate
adult patients' knowledge about cross-infection risk and their
related behaviour.ed by Elsevier B.V. All rights reserved.
Fig. 2. Patients' beliefs about method of acquisition of infection.
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All patients attending a clinic appointment at the West
Midlands Adult CF Centre during June and July 2005 were
offered a questionnaire to complete. Questionnaires were
also offered to in-patients who were due to attend the clinic
during the same period. Questionnaires were posted to
8 patients colonized with the B. cepacia complex, who
attended a separate clinic. After 10 patients had completed a
pilot questionnaire, the results were examined and the
questionnaire updated. Local ethical committee approval
was given.
Data were collected from the questionnaires and the
following information was gathered from patients' hospital
notes: age, sex, height, weight, best spirometry within the
last 3 months, complications of CF (diabetes, liver disease,
renal impairment, transplantation, others), antibiotic prophy-
laxis, number of courses of intravenous antibiotics over the
previous 12 months, and microbiology of sputum samples
over the previous 12 months.
3. Results
3.1. Patient demographics
Of the 184 patients who attended clinic or were posted a
questionnaire, 94 (51.1%) completed the questionnaire.
Demographic data were available for 90: 58.9% were
male, mean age (SD) was 27.2 (8.5) years, mean BMI
(SD) was 22.2 (3.4), mean FEV1 (SD) 62.1 (26.9) %
predicted, mean number of courses (SD) of intravenous
antibiotics in the previous year was 2.8 (2.6). 87.8%, 32.2%,
12.2% and 2.2% had at least one isolation in the previous
year of P. aeruginosa, S. aureus, MRSA, and B. cepacia
complex, respectively. Mean (SD) number of sputum
samples sent in the previous year was 10.7 (7.9). 34.4%
had diabetes mellitus, 23.3% had CF related liver disease and
3.3% had chronic renal impairment.Fig. 1. Patients' estimates of lifetime risk of infection. NR= no response. NI =
“no idea”.3.2. Knowledge
60 respondents (63.8%) said they had been advised not to
mix with other patients who had CF, 33 respondents (35.1%)
said they had not received any advice and 1 (1.1%) did not
respond to the question.
Figs. 1–3 are frequency charts showing (1) respondents'
estimates of lifetime risk of infection with each bacterium,
(2) respondents' beliefs about how each bacterium is
acquired, and (3) respondents' beliefs about the conse-
quences of infection with each bacterium. Table 1 shows the
levels of concern patients expressed about each bacterium.
3.3. Behaviour
Table 2 shows the proportion of patients who mixed with
other people with CF. Of the 20 patients who did mix with
others, 16 (80.0%) reported that they had been advised
against this activity. Of the 48 who deliberately avoidedFig. 3. Patients' beliefs about the consequences of infection.
Table 1
Levels of concern about a bacterium
Bacterium Not at all concerned Extremely concerned
Epidemic P. aeruginosa 29 (31%) 9 (10%)
B. cepacia complex 33 (35%) 14 (15%)
MRSA 21 (22%) 18 (19%)
Table 2
Proportion of patients who mix with other people with CF
Question Yes No No
response
Do you mix with anyone else with CF? 20 (21.3%) 70 (74.5%) 4 (4.3%)
Do you mix while in hospital? 33 (35.1%) 59 (62.8%) 2 (2.1%)
Do you mix during physio or nebulizer
therapy?
6 (6.4%) 82 (87.2%) 6 (6.4%)
Do you deliberately avoid contact? 48 (51.1%) 43 (45.7%) 3 (3.2%)
To avoid infections in general? 46 (95.8%) 2 (4.2%) 0 (0.0%)
To avoid B. cepacia complex in
particular?
29 (60.4%) 18 (37.5%) 1 (2.1%)
To avoid epidemic P. aeruginosa? 32 (66.7%) 15 (21.2%) 1 (2.1%)
To avoid MRSA? 22 (45.8%) 25 (52.1%) 1 (2.1%)
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suffer as a result. Of the 43 who did not avoid contact, 10
(23.3%) said that their quality of life would suffer a
‘significant amount’ or ‘a great deal’ if they were to begin
avoiding others.
4. Discussion
4.1. Knowledge
The majority of respondents had been advised not to mix
with other people who had CF. Despite this advice,
knowledge about the risk of cross-infection was very poor.
Most had no idea of the risk of becoming infected with the
three important pathogens asked about in the questionnaire,
and the remainder estimated risks across a broad spectrum
from 1% to 90%. In general, estimates of lifetime risk are 3 to
8%, with occasional epidemics of 30%, for B. cepacia
complex [7,22,23], 20 to 30% for epidemic strains of P.
aeruginosa [9,10,24], and 3% for MRSA [19]. Our centre
does not differ significantly from these figures.
Similarly, a significant proportion did not know how
these infections were acquired. The most common method of
acquisition for all 3 bacteria was thought to be cross-
infection from other patients, followed by acquisition from
the environment. As far as the B. cepacia complex and P.
aeruginosa are concerned, these views are broadly consistent
with the evidence that most patients harbour unique strains
which are presumably environmentally acquired, and other
have epidemic strains which may have been acquired by
cross-infection [6,7,15,25–32]. Any uncertainty on the part
of patients with CF may be at least in part due to the
uncertainty that exists in the scientific community [33,34]. It
was interesting, in the light of recent political campaigns, to
note how many mentioned “dirty” or “unclean” hospital
wards (see Fig. 2) when there is very little evidence that
MRSA is linked with ward cleanliness per se.
A significant proportion had poor knowledge of the
consequences of infection with these bacteria. Although it is
possible for patients to remain stable after colonization with
B. cepacia complex or epidemic strains of P. aeruginosa,
there is evidence that both may increase morbidity and
mortality [11–13,23,30,35]. In contrast there is much less
evidence that MRSA contributes to morbidity or mortality
[19,36,37], yet a significant number of patients thought that
it did. Levels of concern also reflected a bias towards higher
anxiety about MRSA than B. cepacia complex or epidemic
P. aeruginosa. This may reflect the recent increase inmedia coverage of MRSA. One respondent (a teacher)
commented that they had been banned from work until they
had 3 clear screens, another respondent commented that
there was “a lot of hype about [MRSA] in the press” and
another sited a party political election campaign as the source
of their knowledge. It was interesting to note that 2 patients
mentioned refusal for transplantation as a result of MRSA
infection, whereas nobody mentioned this with regard to B.
cepacia complex infection.
4.2. Behaviour
Only the minority (21.3%) said they mixed with other
people who had CF, yet more (35.1%) said they did mix with
other patients with CF whilst in hospital. It is interesting to
note that patients didn't necessarily consider this in-patient
contact as mixing with other patients. More worrying still,
6.4% said they were present while other patients were
performing physiotherapy or using a nebulizer; activities
which are known to increase the airborne bacterial load and
risk of cross-infection [38].
Of those who mixed with others, a significant proportion
(51.1%) said their quality of life would not suffer at all if they
avoided others with CF, with only 23.3% saying their quality
of life would be significantly or greatly affected. Therefore
the behaviour of these patients as a group does not seem to
reflect their need for contact with other people with CF. This
may reflect a lack of consideration of the risk of cross-
infection or a belief that the risk is low.
The proportion of patients who mixed with others despite
receiving advice against such activity is worrying. Most of
the advice was received from members of the CF team (data
not shown) and would have been given during clinic or in-
patient discussions. Only a few patients mentioned having
written advice. It is possible that written formal information
would be a more potent influence on behaviour.
Most respondents who avoided other patients did so to
avoid cross-infection. Interestingly, more were trying to
avoid B. cepacia complex and epidemic P. aeruginosa than
MRSA, even though worries about MRSAwere greater. This
265D.J. Waine et al. / Journal of Cystic Fibrosis 6 (2007) 262–266indicates that worries about cross-infection do not necessar-
ily determine behaviour.
It is important to note that these data pertain to patients
treated at the West Midlands Adult CF Unit. Though the
findings may be different at other centres, these data
highlight the importance of not making assumptions about
patients' knowledge and behaviour. Additionally, only
51.1% of patients attending the clinic completed the
questionnaire. We are unable to retrospectively ascertain
why the other patients did not fill in the questionnaire, but
response rates of this order are not unexpected [39,40].
5. Conclusions
In this questionnaire-based descriptional study of adult
patients with CF we found that, despite a high proportion
having received advice not tomix with other people who have
CF, respondents had a poor idea of the lifetime risk and the
clinical consequences of acquiring infection with B. cepacia
complex, epidemic strains of P. aeruginosa, or MRSA. There
was a bias towards overestimating the impact of MRSA and
underestimating that of the B. cepacia complex and epidemic
strains of P. aeruginosa. Levels of worry about the different
bacteria reflected this bias (see Table 1).
In practice, 20–35% of patients mixed with other people
with CF, and a small number (6.5%) spent time in the same
room during physiotherapy or nebulized therapy, although
the majority (51.1%) reported that their quality of life would
not suffer by avoiding other people with CF. Of those who
did avoid other people with CF, the majority (62.5%) did so
to avoid cross-infection and most reported that their quality
of life did not suffer as a result.
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